SAFETY AND EFFICACY OF OSIMERTINIB AS A THERAPY IN PATIENTS WITH EGFR T790M POSITIVE NON SMALL CELL LUNG CANCER PATIENTS: A SYSTEMATIC REVIEW

被引：0
|
作者：
Gadi, H. R. [1 ]
Ganta, M. R. [1 ]
Voleti, V. B. [1 ]
Rayavarapu, J. E. [1 ]
Thatavarti, R. [1 ]
机构：
[1] Excelra Knowledge Solut, Hyderabad, Andhra Pradesh, India
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.119
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN37
引用
收藏
页码：A418 / A418
页数：1
相关论文
共 50 条
  • [1] The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer
    Gao, Xin
    Le, Xiuning
    Costa, Daniel B.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (04) : 383 - 390
  • [2] Differential efficacy of Osimertinib in EGFR T790M positive non-small cell lung cancer by metastatic site
    Uematsu, Shinya
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 109 - 109
  • [3] Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
    Soejima, Kenzo
    Yasuda, Hiroyuki
    Hirano, Toshiyuki
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (01) : 31 - 38
  • [4] Practical use of osimertinib in Japanese patients with EGFR T790M mutation positive advanced non-small-cell lung cancer
    Kotake, M.
    Murakami, H.
    Naito, T.
    Takahashi, T.
    Kenmotsu, H.
    Ono, A.
    Wakuda, K.
    Nakashima, K.
    Omori, S.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [5] Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status
    Nakashima, Kazuhisa
    Kimura, Madoka
    Akamatsu, Hiroaki
    Daga, Haruko
    Imai, Hisao
    Taira, Tetsuhiko
    Ko, Ryo
    Hisamatsu, Yasushi
    Nishino, Kazumi
    Sugimoto, Takeya
    Miyashita, Yosuke
    Takahashi, Toshiaki
    Kumagai, Toru
    Yamamoto, Nobuyuki
    Murakami, Haruyasu
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (07) : 671 - 675
  • [6] EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
    Zheng, Qiufan
    Hong, Shaodong
    Huang, Yan
    Zhao, Hongyun
    Yang, Yunpeng
    Hou, Xue
    Zhao, Yuanyuan
    Ma, Yuxiang
    Zhou, Ting
    Zhang, Yaxiong
    Fang, Wenfeng
    Zhang, Li
    [J]. CLINICAL AND TRANSLATIONAL MEDICINE, 2020, 9 (01):
  • [7] Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
    Skoulidis, Ferdinandos
    Papadimitrakopoulou, Vassiliki A.
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (03) : 618 - 622
  • [8] Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
    Khozin, Sean
    Weinstock, Chana
    Blumenthal, Gideon M.
    Cheng, Joyce
    He, Kun
    Zhuang, Luning
    Zhao, Hong
    Charlab, Rosane
    Fan, Ingrid
    Keegan, Patricia
    Pazdur, Richard
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (09) : 2131 - 2135
  • [9] Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients with Both T790M and Sensitizing EGFR Mutation
    Lee, J. C.
    Yang, S.
    Oh, D. K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S806 - S807
  • [10] Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation
    Miyashita, Yosuke
    Ko, Ryo
    Shimada, Naoko
    Mitsuishi, Yoichiro
    Miura, Keita
    Matsumoto, Naohisa
    Asao, Tetsuhiko
    Shukuya, Takehito
    Shibayama, Rina
    Koyama, Ryo
    Takahashi, Kazuhisa
    [J]. THORACIC CANCER, 2021, 12 (03) : 329 - 338
12345